Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

Starting soon · Phase 3

Conditions studied: Medulloblastoma

In brief

This is a trial to compare neurocognitive outcomes in the intent-to-treat population 2.5 years after diagnosis between patients with newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC amplified MF randomized to the interventional arms A ("Head Start 4") or B (HIT-SKK).

Key facts

Study ID

NCT07291102

Run by

Nationwide Children's Hospital

People needed

96

Starts

2026-07-01

Expected to finish

2038-10-01

Last updated by the study team

2025-12-18

Who can join

Age: any, up to 5. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Children's of Alabama — Birmingham, Alabama, United States
• Nationwide Children's Hospital — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.